Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
Cutaneous Melanoma
Explore 142 assets in Cutaneous Melanoma →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Laboratorio Pablo Cassará S.R.L.
Modality
vaccine
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01729663CT.gov Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients | — | Unknown | — | — | — |
NCT00003715CT.gov Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain (this asset) | Laboratorio Pablo Cassará S.R.L. | P2/3 | B · 58 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Cediranib | Jonsson Comprehensive Cancer Center | P3 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Alzheimer Disease | — | P2 | BB · 64 |
| Metastatic Melanoma | — | P2/3 | B · 61 |
| Superficial Urinary Bladder Carcinoma | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bacillus Calmette-Guerin Live Antigen, Unspecified Substrain in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bacillus-calmette-guerin-live-antigen-unspecified-substrain-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →